NEC, together with the Japan Cancer Research Institute (JFCR) and Taiho Pharmaceutical, publicized a partnership to create and produce neoantigen-based cancer vaccines that will be shared. The focus of these vaccines is on the tumour-specific neoantigens that are common in several patients aiming to give "off-the-shelf" immunotherapy options instead of completely personalized ones. This action indicates the increasing trend in cancer-vaccine research and development and could lead to partnerships and licensing opportunities worldwide in the future.
Source Reference:
NEC / JFCR / Taiho press release — Nov 28, 2025 NEC Global
Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.